We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-7.53%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$319M
AUM Growth
-$42M
Cap. Flow
-$13.7M
Cap. Flow %
-4.3%
Top 10 Hldgs %
40.4%
Holding
86
New
14
Increased
23
Reduced
18
Closed
23

Top Buys

1
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M
2
BHVN icon
Biohaven
BHVN
+$8.11M
3
CGON icon
CG Oncology
CGON
+$6.41M
4
KRRO icon
Korro Bio
KRRO
+$5.53M
5
SYRE icon
Spyre Therapeutics
SYRE
+$5.07M

Top Sells

1
SRPT icon
Sarepta Therapeutics
SRPT
+$8.99M
2
JBIO
Jade Biosciences
JBIO
+$6.65M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.92M
4
TGTX icon
TG Therapeutics
TGTX
+$5.19M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.44M

Sector Composition

1 Healthcare 89.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
51
CALL
Annexon
ANNX
$950M
$1.05M 0.33%
+214,500
New +$1.11M
WVE icon
52
Wave Life Sciences
WVE
$1.12B
$998K 0.31%
+200,000
New +$1.14M
RAPT
53
CALL
DELISTED
RAPT Therapeutics
RAPT
$915K 0.29%
37,500
– –
ARWR icon
54
Arrowhead Research
ARWR
$10.5B
$910K 0.28%
35,000
– –
SGMT icon
55
Sagimet Biosciences
SGMT
$483M
$770K 0.24%
225,000
– –
ITCI
56
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$685K 0.21%
+10,000
New +$694K
MGNX icon
57
MacroGenics
MGNX
$285M
$638K 0.2%
+150,000
New +$1.46M
PMVP icon
58
PMV Pharmaceuticals
PMVP
$71.5M
$608K 0.19%
375,000
-300,000
-44% -$541K
PTCT icon
59
PTC Therapeutics
PTCT
$6.52B
$581K 0.18%
+19,000
New +$615K
RVNC
60
DELISTED
Revance Therapeutics, Inc.
RVNC
$578K 0.18%
225,000
-225,000
-50% -$768K
NTLA icon
61
Intellia Therapeutics
NTLA
$1.59B
$560K 0.18%
25,000
– –
ANTX icon
62
AN2 Therapeutics
ANTX
$169M
$472K 0.15%
219,331
– –
CTMX icon
63
CytomX Therapeutics
CTMX
$788M
$366K 0.11%
300,000
-300,000
-50% -$597K
ACAD icon
64
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-200,000
Closed -$3.7M
ALT icon
65
Altimmune
ALT
$558M
– –
-250,000
Closed -$2.54M
AQST icon
66
Aquestive Therapeutics
AQST
$517M
– –
-702,941
Closed -$2.99M
ATXS
67
DELISTED
Astria Therapeutics
ATXS
– –
-115,000
Closed -$1.62M
JBIO
68
Jade Biosciences
JBIO
$1.27B
– –
-6,429
Closed -$6.65M
COGT icon
69
Cogent Biosciences
COGT
$6.68B
– –
-450,000
Closed -$3.02M
CYTK icon
70
CALL
Cytokinetics
CYTK
$10.9B
– –
-75,000
Closed -$5.26M
EYPT icon
71
EyePoint Inc
EYPT
$1.12B
– –
-90,000
Closed -$1.86M
GERN icon
72
Geron
GERN
$924M
– –
-800,000
Closed -$2.64M
GPCR icon
73
Structure Therapeutics
GPCR
$3.45B
– –
-75,000
Closed -$3.21M
IMVT icon
74
CALL
Immunovant
IMVT
$8.27B
– –
-150,000
Closed -$4.85M
KALV
75
DELISTED
KalVista Pharmaceuticals
KALV
– –
-200,000
Closed -$2.37M
1 2
3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ghost Tree Capital held 86 positions worth $319M, down 12% from $361M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ghost Tree Capital withdrew a net $13.7M in Q2 2024, closing 23 positions and reducing 18 holdings. Its most notable exit was Jade Biosciences, an estimated $6.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Ascendis Pharma A/S worth $11.8M.

  • Ghost Tree Capital's largest Q2 2024 buy was Ascendis Pharma A/S: 86,721 shares worth $11.8M.
  • Ghost Tree Capital added most to Biohaven in Q2 2024, an estimated $8.11M increase.
  • Ghost Tree Capital's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $8.99M.
  • Ghost Tree Capital fully exited Jade Biosciences in Q2 2024, selling an estimated $6.65M.
  • Ghost Tree Capital's ten largest holdings make up 40% of its $319M portfolio in Q2 2024.
  • Ghost Tree Capital opened 14 new positions and closed 23 in Q2 2024.
  • Ghost Tree Capital's portfolio value fell 12% quarter-over-quarter to $319M.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.